This paper reviews the evolving landscape of systemic therapy for hepatocellular carcinoma (HCC), focusing on combination regimens including doublets, triplets, and emerging multi-agent strategies.
The source text provided contains only the title, DOI, journal, and publication date — no abstract, methods, results, or conclusions are available for extraction.
